144 related articles for article (PubMed ID: 7044528)
1. Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone.
Powles TJ; Gordon C; Coombes RC
Cancer Res; 1982 Aug; 42(8 Suppl):3458s-3460s. PubMed ID: 7044528
[TBL] [Abstract][Full Text] [Related]
2. Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.
Ingle JN; Green SJ; Ahmann DL; Edmonson JH; Nichols WC; Frytak S; Rubin J
Cancer Res; 1982 Aug; 42(8 Suppl):3461s-3467s. PubMed ID: 7044529
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.
Smith IE; Harris AL; Morgan M; Gazet JC; McKinna JA
Cancer Res; 1982 Aug; 42(8 Suppl):3430s-3433s. PubMed ID: 7044525
[TBL] [Abstract][Full Text] [Related]
4. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen vs. tamoxifen plus aminoglutethimide and hydrocortisone.
Rose C; Kamby C; Mouridsen HT; Bastholt L; Brincker H; Skovgaard-Poulsen H; Andersen AP; Loft H; Dombernowsky P; Andersen KW
Breast Cancer Res Treat; 1986; 7 Suppl():S45-50. PubMed ID: 3527306
[TBL] [Abstract][Full Text] [Related]
5. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially.
Powles TJ; Ashley S; Ford HT; Gazet JC; Nash AG; Neville AM; Coombes RC
Lancet; 1984 Jun; 1(8391):1369-73. PubMed ID: 6145832
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of aminoglutethimide versus tamoxifen in metastatic breast cancer.
Lipton A; Harvey HA; Santen RJ; Boucher A; White D; Bernath A; Dixon R; Richards G; Shafik A
Cancer Res; 1982 Aug; 42(8 Suppl):3434s-3436s. PubMed ID: 7044526
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen and aminoglutethimide in advanced breast cancer.
Corkery J; Leonard RC; Henderson IC; Gelman RS; Hourihan J; Ascoli DM; Salhanick HA
Cancer Res; 1982 Aug; 42(8 Suppl):3409s-3414s. PubMed ID: 7044523
[TBL] [Abstract][Full Text] [Related]
8. [Low-dose aminoglutethimide (500 mg/day) and hydrocortisone (30 mg/day) in advanced cancer of breast].
Bonneterre J; Pion JM; Demaille A
Bull Cancer; 1987; 74(3):241-7. PubMed ID: 3304478
[TBL] [Abstract][Full Text] [Related]
9. [A comparison of two doses of tamoxifen in patients with advanced breast cancer: 20 mg/day versus 40 mg/day].
Takatsuka Y; Yayoi E; Inaji H; Aikawa T
Gan To Kagaku Ryoho; 1989 May; 16(5):2093-7. PubMed ID: 2658841
[TBL] [Abstract][Full Text] [Related]
10. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
11. [Aminoglutethimide and aminoglutethimide+tamoxifen treatment for advanced breast cancer].
Hisamatsu K; Nomura Y; Tashiro H
Gan To Kagaku Ryoho; 1992 Oct; 19(12):2017-23. PubMed ID: 1417009
[TBL] [Abstract][Full Text] [Related]
12. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer.
Harvey HA; Lipton A; White DS; Santen RJ; Boucher AE; Shafik AS; Dixon RJ
Cancer Res; 1982 Aug; 42(8 Suppl):3451s-3453s. PubMed ID: 6177405
[TBL] [Abstract][Full Text] [Related]
13. Treatment of metastatic breast cancer with aminoglutethimide after progression on chemotherapy and/or hormonal therapy with tamoxifen.
Brufman G; Biran S
Eur J Surg Oncol; 1985 Mar; 11(1):27-31. PubMed ID: 2985452
[TBL] [Abstract][Full Text] [Related]
14. [Aminoglutethimide in advanced breast cancer. Multicenter trial comparing 500 mg and 1000 mg per day].
Bonneterre J; Coppens H; Mauriac L; Rouesse J; Fargeot P; Metz R; Armand JP; Mathieu A; Tubiana M; Cappelaere P
Acta Clin Belg Suppl; 1986; 11():41-8. PubMed ID: 3521171
[No Abstract] [Full Text] [Related]
15. Aminoglutethimide as second line endocrine therapy in advanced breast cancer.
Brufman G; Biran S
Anticancer Res; 1986; 6(5):1065-8. PubMed ID: 3800315
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer.
Coombes RC; Powles TJ; Rees LH; Ratcliffe WA; Nash AG; Henk M; Ford HT; Gazet JC; Neville AM
Br J Cancer; 1982 Jul; 46(1):30-4. PubMed ID: 7104195
[TBL] [Abstract][Full Text] [Related]
17. Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer.
Kaye SB; Woods RL; Fox RM; Coates AS; Tattersall MH
Cancer Res; 1982 Aug; 42(8 Suppl):3445s-3447s. PubMed ID: 6177404
[TBL] [Abstract][Full Text] [Related]
18. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
19. Aminoglutethimide in the treatment of advanced postmenopausal breast cancer.
Harris AL; Powles TJ; Smith IE
Cancer Res; 1982 Aug; 42(8 Suppl):3405s-3408s. PubMed ID: 7083207
[TBL] [Abstract][Full Text] [Related]
20. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
